Role of the endocannabinoid system in Alzheimer's disease: new perspectives.

  title={Role of the endocannabinoid system in Alzheimer's disease: new perspectives.},
  author={Mar{\'i}a Ruth Pazos and Estefan{\'i}a N{\'u}{\~n}ez and Cristina Benito and Rosa Mar{\'i}a Tol{\'o}n and Julián Romero},
  journal={Life sciences},
  volume={75 16},

The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses.

There is evidence, from in vivo studies on beta-amyloid-induced neurotoxicity, also for a possible causative role of endocannabinoids in the impairment in memory retention, which is typical of AD, which might open the way to the use of cannabinoid receptor antagonists as therapeutic drugs for the treatment of cognitive deficits in the more advanced phases of this disorder.

The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer's disease.

The role of endocannabinoid signaling in AD is recapitulate and the probable mechanisms through which modulators of the endOCannabinoid system provide their effects are highlighted, thus highlighting how this target might provide more advantages over other therapeutic targets.

The therapeutic potential of the endocannabinoid system for Alzheimer's disease

Future research should focus on the evaluation of the effects of manipulations to the endocannabinoid system in established animal models for AD, combined with early-phase studies in humans.

The Endocannabinoid System in the Physiology and Pathology of the Basal Ganglia

In this chapter, the anatomical, neurochemical, electrophysiological, and pharmacological bases that sustain the importance of the cannabinoid system in basal ganglia function are reviewed, attempting to present current information and future lines for research on the therapeutic potential of this system inBasal ganglia disorders.

The Endocannabinoid System as an Emerging Target of Pharmacotherapy

A comprehensive overview on the current state of knowledge of the endocannabinoid system as a target of pharmacotherapy is provided.

A Glial Endogenous Cannabinoid System Is Upregulated in the Brains of Macaques with Simian Immunodeficiency Virus-Induced Encephalitis

The results suggest that the endocannabinoid system may participate in the development of human immunodeficiency virus-induced encephalitis, because activation of CB2 receptors expressed by immune cells is likely to reduce their antiviral response and thus could favor the CNS entry of infected monocytes.

A molecular link between the active component of marijuana and Alzheimer's disease pathology.

It is demonstrated that the active component of marijuana, Delta9-tetrahydrocannabinol (THC), competitively inhibits the enzyme acetylcholinesterase (AChE) as well as prevents AChE-induced amyloid beta-peptide aggregation, the key pathological marker of Alzheimer's disease.



Cannabinoids and neuroinflammation

The aim of this review is to identify immune functions modulated by cannabinoids that could account for their anti‐inflammatory effects in these animal models of clinical neuroinflammatory conditions.

Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains

Results show that both fatty acid amide hydrolase and cannabinoid CB2 receptors are abundantly and selectively expressed in neuritic plaque-associated astrocytes and microglia, respectively, whereas the expression of CB1 receptors remains unchanged.

Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis

Treatment with the synthetic cannabinoids WIN 55,212–2, ACEA, and JWH-015 during established disease significantly improved the neurological deficits in a long-lasting way and the possible involvement of cannabinoid receptor CB2 would enable nonpsychoactive therapy suitable for long-term use.

Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology.

A more thorough characterization of the roles of endocannabinoids in health and disease will be necessary to define the significance ofendocannabinoid inactivation mechanisms as targets for therapeutic drugs.

Brain monoglyceride lipase participating in endocannabinoid inactivation

The results suggest that hydrolysis by means of MGL is a primary mechanism for 2-AG inactivation in intact neurons, and not on the accumulation of anandamide, another endocannabinoid lipid.